Neuroprotective Strategies for Ischemic Stroke—Future Perspectives
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Ischemic stroke is the main cause of death and the most common cause of acquired physical disability worldwide. Recent demographic changes increase the relevance of stroke and its sequelae. The acute treatment for stroke is restricted to causative recanalization and restoration of cerebral blood flow, including both intravenous thrombolysis and mechanical thrombectomy. Still, only a limited number of patients are eligible for these time-sensitive treatments. Hence, new neuroprotective approaches are urgently needed. Neuroprotection is thus defined as an intervention resulting in the preservation, recovery, and/or regeneration of the nervous system by interfering with the ischemic-triggered stroke cascade. Despite numerous preclinical studies generating promising data for several neuroprotective agents, successful bench-to-bedside translations are still lacking. The present study provides an overview of current approaches in the research field of neuroprotective stroke treatment. Aside from “traditional” neuroprotective drugs focusing on inflammation, cell death, and excitotoxicity, stem-cell-based treatment methods are also considered. Furthermore, an overview of a prospective neuroprotective method using extracellular vesicles that are secreted from various stem cell sources, including neural stem cells and bone marrow stem cells, is also given. The review concludes with a short discussion on the microbiota–gut–brain axis that may serve as a potential target for future neuroprotective therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathobiology of ischaemic stroke: an integrated view
Dirnagl, U., Iadecola, C., & Moskowitz, M. A. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01401-0 · Cited by 3,943
Pathophysiology and treatment of stroke: present status and future perspectives
Kuriakose, D., & Xiao, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207609 · Cited by 1,350 · cited 11×
“Invading neutrophils secrete matrix metalloproteinases, which lead to the breakdown of tight junctions that physiologically ensure the integrity of the BBB [7].”
BackgroundInfluentialCommensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells
Benakis, C., Brea, D., Caballero, S., Faraco, G., Moore, J., Murphy, M., Sita, G., Racchumi, G., Ling, L., Pamer, E. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4068 · Cited by 1,114
Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn
Xu, K., Gao, X., Xia, G., Chen, M., Zeng, N., Wang, S., You, C., Tian, X., Di, H., Tang, W., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323263 · Cited by 308
Prasad, K., Sharma, A., Garg, A., Mohanty, S., Bhatnagar, S., Johri, S., Singh, K. K., Nair, V., Sarkar, R. S., Gorthi, S. P., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.007028 · Cited by 307 · cited 1×
“However, Prasad and colleagues revealed in the first multicenter randomized controlled trial intravenous given BMCSs are safe but have no beneficial effect on stroke outcome (Table 3) [58].”
BackgroundMeta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke
Vu, Q., Xie, K., Eckert, M., Zhao, W., & Cramer, S. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000278 · Cited by 235 · cited 2×
“As a result, the trials revealed an overall very substantial treatment effect and very robust results in terms of different species, delivery routes, MSC sources, time, dose, and the presence of comorbidities [65].”
MethodResultAnti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy
Garwood, C. J., Cooper, J. D., Hanger, D. P., & Noble, W. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00136 · Cited by 106
Cited by
Hermann, D. M., Bacigaluppi, M., Bassetti, C. L., Bassotti, G., Boltze, J., Chan, A., Dalkara, T., Denes, A., Diez-Tejedor, E., Dodel, R., et al. (2025) · Exploration of Neuroscience · doi:10.37349/en.2025.1006106 · Cited by 13
“In ischemic stroke, several studies aimed at establishing neuroprotective drugs [26, 27].”
Self-citation
Metadata
- Authors
- Haupt, M., Gerner, S. T., Bähr, M., & Doeppner, T. R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-02-22
- Volume
- 24
- Issue
- 5
- Pages
- 4334
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4321497223
- Cited by
- 202
- References
- 7
- FWCI
- 33.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.